Hyperpigmentation: hydroquinone, cysteamine and TXA

Comparing hydroquinone 4%, cysteamine, tranexamic acid and kojic acid requires more than ranking ingredient names. Route, concentration, vehicle, companion ingredients, diagnosis and study design all change what a result means.

TL;DR: Hydroquinone is a clinician-supervised depigmenting medicine in many settings. Cysteamine has comparative melasma data, but one recent trial tested combination formulations. Tranexamic acid evidence must be separated into topical, oral and intradermal routes. A small open-label comparison of cysteamine and kojic acid did not prove one superior. Sun protection and diagnosis remain central.

First identify the pigment problem

Melasma, post-inflammatory hyperpigmentation and a changing pigmented lesion are not interchangeable. Melasma is usually diagnosed clinically; persistent, spreading, symptomatic or unusual pigmentation deserves assessment before stronger treatment. The American Academy of Dermatology melasma guide describes sun protection and clinician-directed options without promising a universal best active.

UV and visible light can matter in melasma, so choose broad-spectrum sunscreen you can apply as directed. A tinted product may add visible-light attenuation depending on its pigments and tested formulation; see our tinted sunscreen evidence guide.

Hydroquinone 4%

Hydroquinone inhibits pigment production and is used in medical treatment of selected hyperpigmentation. Access and approved formulations vary by country. Four percent should not be treated as a permanent cosmetic routine: a clinician should confirm the diagnosis, specify duration and review irritation or unusual darkening.

Evidence from a prescription combination cannot be assigned to hydroquinone alone. Likewise, the outcome of a compounded or pharmacy product does not establish that an unverified online product has the same identity, concentration, stability or safety.

Cysteamine

Cysteamine is used in topical depigmenting formulations. PMID 40127492 reported a double-blind randomized comparison involving cysteamine plus ectoin and hydroquinone plus ectoin formulations. Both groups improved and the reported between-group difference was not statistically significant.

That study supports further comparison of the tested formulations. It does not prove that cysteamine alone equals hydroquinone alone, that every 5 percent product is equivalent, or that a branded product can be used indefinitely. Contact time and frequency should follow the tested product or clinician instructions.

Tranexamic acid: route changes the answer

Tranexamic acid appears in topical cosmetics and is also studied by oral or intradermal routes under medical supervision. These routes have different exposure, risks and evidence; results must not be transferred from one to another.

The 2025 network meta-analysis indexed as PMID 41149049 compared multiple melasma interventions. Its leading comparisons involved platelet-rich plasma and combinations including oral and intradermal tranexamic acid. Those findings cannot be transferred to a topical cosmetic serum or used as a topical ranking.

Oral and intradermal use require a qualified clinician. A topical product may be considered on its own evidence and label, but the word “tranexamic” is not enough to borrow results from another route.

Kojic acid and the limits of one small study

Kojic acid is used in cosmetic depigmenting formulations and can irritate some users. PMID 40296942 describes an open-label study of 72 women comparing 5 percent cysteamine with 2 percent kojic acid over 16 weeks. Both groups improved; the between-group difference reported in the abstract was not statistically significant.

That result does not show that kojic acid has a lower maximum effect, nor does it define either ingredient's place in every melasma routine. Larger blinded trials and formulation-specific evidence would be needed for a firm hierarchy.

Evidence-aware comparison

Option	What can be said cautiously	What the cited studies do not prove
Hydroquinone 4%	Clinician-supervised option used for selected pigment disorders	Safe indefinite self-treatment or equivalence of unverified products
Cysteamine	Comparative data exist for specific topical formulations	Ingredient-alone equivalence across brands and vehicles
Topical tranexamic acid	Cosmetic and clinical formulations exist	The benefits or risks of oral, injected or procedural treatment
Oral/intradermal tranexamic acid	Studied as medical interventions and combinations	That a topical serum produces the same result
Kojic acid	Small comparative data and cosmetic use exist	Proven inferiority or a universal maintenance role

Building a conservative routine

Confirm what is being treated, especially if pigmentation is changing or atypical.
Use broad-spectrum sun protection according to its label.
Introduce one leave-on treatment at a time and stop if significant irritation develops.
Do not stack prescription medicines or copy an oral/injection protocol into skincare.
Review response on the schedule supported by the specific product or clinician, not a universal eight-week promise.

Irritation itself can worsen post-inflammatory pigmentation. More actives are therefore not automatically better, particularly on skin that marks easily. A simple moisturiser may improve tolerance but does not turn an unsupported combination into an evidence-based one.

Safety questions

Hydroquinone and any oral or injected tranexamic acid need product- and patient-specific medical review. Pregnancy, breastfeeding, clotting history, other medicines and unexplained pigmentation cannot be handled by a blanket ingredient statement. Ask a qualified clinician or pharmacist before use.

Seek prompt assessment for a spot that changes shape, colour or size, bleeds, becomes painful, or looks different from the others. A cosmetic comparison is not a skin-cancer screening tool.

Frequently asked questions

Is cysteamine as effective as hydroquinone 4%?

One 2025 trial found improvement in both tested combination-formulation groups without a statistically significant between-group difference. That does not establish ingredient-alone equivalence across all products.

What does the cited meta-analysis say about topical tranexamic acid?

The cited network meta-analysis does not support that conclusion. Its results include procedural, oral and intradermal interventions. Topical treatment needs topical formulation-specific evidence.

Is kojic acid only useful for maintenance?

The small cited open-label trial does not define that role or prove a lower ceiling. Choice should reflect the diagnosis, formulation, tolerance and available evidence.

Can I combine all four?

Not from this evidence. Combining active medicines can increase irritation and other risks. Follow the directions for the actual product and a clinician's plan when prescriptions are involved.

Sources

Kusumawardani A. et al. (2025). Comparative trial of cysteamine/ectoin and hydroquinone/ectoin formulations for melasma. PubMed PMID 40127492
Patil R. et al. (2025). Open-label comparison of 5% cysteamine and 2% kojic acid creams. PubMed PMID 40296942
Leung J.H. et al. (2025). Network meta-analysis of melasma interventions. PubMed PMID 41149049
American Academy of Dermatology: melasma diagnosis and treatment